Cargando…

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer

INTRODUCTION: Quality assurance (QA) of treatment plans in clinical trials improves protocol compliance and patient outcomes. Retrospective use of knowledge-based-planning (KBP) in clinical trials has demonstrated improved treatment plan quality and consistency. We report the results of prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardcastle, Nicholas, Cook, Olivia, Ray, Xenia, Moore, Alisha, Moore, Kevin L., Pryor, David, Rossi, Alana, Foroudi, Farshad, Kron, Tomas, Siva, Shankar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330099/
https://www.ncbi.nlm.nih.gov/pubmed/34344402
http://dx.doi.org/10.1186/s13014-021-01820-7
_version_ 1783732631336124416
author Hardcastle, Nicholas
Cook, Olivia
Ray, Xenia
Moore, Alisha
Moore, Kevin L.
Pryor, David
Rossi, Alana
Foroudi, Farshad
Kron, Tomas
Siva, Shankar
author_facet Hardcastle, Nicholas
Cook, Olivia
Ray, Xenia
Moore, Alisha
Moore, Kevin L.
Pryor, David
Rossi, Alana
Foroudi, Farshad
Kron, Tomas
Siva, Shankar
author_sort Hardcastle, Nicholas
collection PubMed
description INTRODUCTION: Quality assurance (QA) of treatment plans in clinical trials improves protocol compliance and patient outcomes. Retrospective use of knowledge-based-planning (KBP) in clinical trials has demonstrated improved treatment plan quality and consistency. We report the results of prospective use of KBP for real-time QA of treatment plan quality in the TROG 15.03 FASTRACK II trial, which evaluates efficacy of stereotactic ablative body radiotherapy (SABR) for kidney cancer. METHODS: A KBP model was generated based on single institution data. For each patient in the KBP phase (open to the last 31 patients in the trial), the treating centre submitted treatment plans 7 days prior to treatment. A treatment plan was created by using the KBP model, which was compared with the submitted plan for each organ-at-risk (OAR) dose constraint. A report comparing each plan for each OAR constraint was provided to the submitting centre within 24 h of receiving the plan. The centre could then modify the plan based on the KBP report, or continue with the existing plan. RESULTS: Real-time feedback using KBP was provided in 24/31 cases. Consistent plan quality was in general achieved between KBP and the submitted plan. KBP review resulted in replan and improvement of OAR dosimetry in two patients. All centres indicated that the feedback was a useful QA check of their treatment plan. CONCLUSION: KBP for real-time treatment plan review was feasible for 24/31 cases, and demonstrated ability to improve treatment plan quality in two cases. Challenges include integration of KBP feedback into clinical timelines, interpretation of KBP results with respect to clinical trade-offs, and determination of appropriate plan quality improvement criteria. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-021-01820-7.
format Online
Article
Text
id pubmed-8330099
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83300992021-08-04 Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer Hardcastle, Nicholas Cook, Olivia Ray, Xenia Moore, Alisha Moore, Kevin L. Pryor, David Rossi, Alana Foroudi, Farshad Kron, Tomas Siva, Shankar Radiat Oncol Research INTRODUCTION: Quality assurance (QA) of treatment plans in clinical trials improves protocol compliance and patient outcomes. Retrospective use of knowledge-based-planning (KBP) in clinical trials has demonstrated improved treatment plan quality and consistency. We report the results of prospective use of KBP for real-time QA of treatment plan quality in the TROG 15.03 FASTRACK II trial, which evaluates efficacy of stereotactic ablative body radiotherapy (SABR) for kidney cancer. METHODS: A KBP model was generated based on single institution data. For each patient in the KBP phase (open to the last 31 patients in the trial), the treating centre submitted treatment plans 7 days prior to treatment. A treatment plan was created by using the KBP model, which was compared with the submitted plan for each organ-at-risk (OAR) dose constraint. A report comparing each plan for each OAR constraint was provided to the submitting centre within 24 h of receiving the plan. The centre could then modify the plan based on the KBP report, or continue with the existing plan. RESULTS: Real-time feedback using KBP was provided in 24/31 cases. Consistent plan quality was in general achieved between KBP and the submitted plan. KBP review resulted in replan and improvement of OAR dosimetry in two patients. All centres indicated that the feedback was a useful QA check of their treatment plan. CONCLUSION: KBP for real-time treatment plan review was feasible for 24/31 cases, and demonstrated ability to improve treatment plan quality in two cases. Challenges include integration of KBP feedback into clinical timelines, interpretation of KBP results with respect to clinical trade-offs, and determination of appropriate plan quality improvement criteria. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-021-01820-7. BioMed Central 2021-08-03 /pmc/articles/PMC8330099/ /pubmed/34344402 http://dx.doi.org/10.1186/s13014-021-01820-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hardcastle, Nicholas
Cook, Olivia
Ray, Xenia
Moore, Alisha
Moore, Kevin L.
Pryor, David
Rossi, Alana
Foroudi, Farshad
Kron, Tomas
Siva, Shankar
Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
title Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
title_full Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
title_fullStr Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
title_full_unstemmed Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
title_short Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
title_sort personalising treatment plan quality review with knowledge-based planning in the trog 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330099/
https://www.ncbi.nlm.nih.gov/pubmed/34344402
http://dx.doi.org/10.1186/s13014-021-01820-7
work_keys_str_mv AT hardcastlenicholas personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT cookolivia personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT rayxenia personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT moorealisha personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT moorekevinl personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT pryordavid personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT rossialana personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT foroudifarshad personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT krontomas personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer
AT sivashankar personalisingtreatmentplanqualityreviewwithknowledgebasedplanninginthetrog1503trialforstereotacticablativebodyradiotherapyinprimarykidneycancer